We are live on ! Find out more
PGNX

Progenics Pharmaceuticals Inc
PGNX

Delisted

PGNX was delisted on the 19th of June, 2020.

Back to rankings

76 hedge funds and large institutions have $219M invested in Progenics Pharmaceuticals Inc in 2014 Q2 according to their latest regulatory filings, with 9 funds opening new positions, 28 increasing their positions, 25 reducing their positions, and 20 closing their positions.

New
Increased
Maintained
Reduced
Closed

21% more call options, than puts

Call options by funds: $948K | Put options by funds: $781K

12% more repeat investments, than reductions

Existing positions increased: 28 | Existing positions reduced: 25

3% more capital invested

Capital invested by funds: $213M → $219M (+$5.72M)

13% less funds holding

Funds holding: 87 → 76 (-11)

55% less first-time investments, than exits

New positions opened: 9 | Existing positions closed: 20

Holders
76
Holders Change
-11
Holders Change %
-12.64%
% of All Funds
2.18%
Holding in Top 10
1
Holding in Top 10 Change
+1
Holding in Top 10 Change %
% of All Funds
0.03%
New
9
Increased
28
Reduced
25
Closed
20
Calls
$948K
Puts
$781K
Net Calls
+$167K
Net Calls Change
+$123K

Top Buyers

Rank Fund Capital Flow
1
BC
Broadfin Capital
New York
+$4.01M
2
HCMT
Highland Capital Management (Texas)
Texas
+$785K
3
Millennium Management
Millennium Management
New York
+$505K
4
JG
Jefferies Group
New York
+$496K
5
PFC
Phocas Financial Corp
California
+$482K

Top Sellers

Rank Fund Capital Flow
1
TCA
Taconic Capital Advisors
New York
-$3.21M
2
Franklin Resources
Franklin Resources
California
-$2.6M
3
NI
Numeric Investors
Massachusetts
-$1.46M
4
Fidelity Investments
Fidelity Investments
Massachusetts
-$1.26M
5
HCM
Highbridge Capital Management
New York
-$708K
Name Holding Trade Value Shares
Change 		Change in
Stake
Franklin Resources
76
Franklin Resources
California
– -$2.6M -636,816 Closed
HCM
77
Highbridge Capital Management
New York
– -$708K -172,960 Closed
OAM
78
Oxford Asset Management
United Kingdom
– -$414K -101,275 Closed
GT
79
Glenmede Trust
Pennsylvania
– -$333K -81,662 Closed
BGA
80
Belmont Global Advisors
Texas
– -$307K -75,000 Closed
Los Angeles Capital Management
81
Los Angeles Capital Management
California
– -$222K -54,170 Closed
UOC
82
UBS O'Connor
Illinois
– -$204K -50,000 Closed
NCCM
83
Nine Chapters Capital Management
New Jersey
– -$180K -44,100 Closed
SG Americas Securities
84
SG Americas Securities
New York
– -$150K -36,759 Closed
Invesco
85
Invesco
Georgia
– -$122K -29,948 Closed
Principal Financial Group
86
Principal Financial Group
Iowa
– -$119K -29,154 Closed
SCA
87
SAC Capital Advisors
Connecticut
– -$118K -28,878 Closed
SCM
88
Stevens Capital Management
Pennsylvania
– -$87K -21,262 Closed
VKH
89
Virtu KCG Holdings
New York
– -$51K -12,578 Closed
D.E. Shaw & Co
90
D.E. Shaw & Co
New York
– -$48K -11,689 Closed
GCP
91
GSA Capital Partners
United Kingdom
– -$41K -10,080 Closed
CCMH
92
Cornerstone Capital Management Holdings
New York
– -$14K -3,500 Closed
PCM
93
Prelude Capital Management
New York
– -$14K -3,500 Closed
BNP Paribas Financial Markets
94
BNP Paribas Financial Markets
France
– -$551 -156 Closed
Ameriprise
95
Ameriprise
Minnesota
– +$38 +10 New
1 2 3
4

PGNX Hedge Fund Activity: Q2 2014 in Review

76 of the 3,479 institutional investors tracked by Wall St. Rank reported a position in Progenics Pharmaceuticals Inc (PGNX) for Q2 2014, worth a combined $219M — up 2.7% from $213M a quarter earlier.

Sellers outnumbered buyers: 20 funds closed out of PGNX and 9 opened new positions — a net loss of 11 holders — while 25 trimmed existing stakes and 28 added.

The largest buyer was Broadfin Capital, adding an estimated $4.01M. The largest seller was Taconic Capital Advisors, exiting entirely with an estimated $3.21M sold.

  • 76 institutional investors held Progenics Pharmaceuticals Inc (PGNX) as of Q2 2014, down from 87 in Q1 2014.
  • Funds reported $219M of Progenics Pharmaceuticals Inc stock for Q2 2014, up 2.7% quarter-over-quarter.
  • 9 funds opened new Progenics Pharmaceuticals Inc positions in Q2 2014 and 20 closed out, a net change of -11 holders.
  • The largest Progenics Pharmaceuticals Inc buyer in Q2 2014 was Broadfin Capital, an estimated $4.01M added.
  • The largest Progenics Pharmaceuticals Inc seller in Q2 2014 was Taconic Capital Advisors, an estimated $3.21M sold.

Based on aggregated 13F filings for Q2 2014.